Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Learn more. No significant difference was seen in time to neutrophil engraftment between the SQ and IV routes of administration of G-CSF in patients who underwent HSCT. After receiving your transplant, your white blood cell count will decrease quickly and will remain low until the new cells begin to grow (engraftment). Between July 2015 and April 2016, G-CSF was administered at our institution using mainly the IV route, and this practice was changed in April 2016, so that the majority of patients were switched to the SQ administration based on provider preference. A fever may also develop. Neutrophil engraftment was measured from the day of transplant (day 0) to the first day of absolute neutrophil count ≥500 cells/mcL for 3 consecutive days. G-CSF is often used via IV or SQ administration to expedite the neutrophil engraftment process. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Patients were assigned to each group according to the route of administration (SQ or IV) for >50% of administrations. Number of times cited according to CrossRef: Reticulated platelets – clinical application and future perspectives. Mossad SB, Longworth DL, Goormastic M, et al. Trivedi M, Martinez S, Corringham S, et al. COVID-19 is an emerging, rapidly evolving situation. Furthermore, few patients were excluded from the study, which may allow the results to be applied to a wider range of HSCT patients. Stem cell journey • HPC transplant (intravenous infusion) • Stem cells circulate via the blood stream • Recovery of neutrophil and platelet counts after the nadir induced by conditioning therapy • Time of engraftment = Number of days between HPC infusion and neutrophil or platelet recovery. Smith TJ, Khatcheressian J, Lyman GH, et al. Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice. We prospectively analyzed 911 follow‐up peripheral blood samples from 44 HSCT‐performed patients and evaluated the performances of the following parameters: WBC, immature granulocyte (IG), hematopoietic stem and progenitor cells (HPC), immature reticulocyte fraction (IRF), immature platelet fraction (IPF), platelet distribution width (PDW), mean platelet volume (MPV), and platelet larger cell ratio (P‐LCR). The chi square or Fisher’s exact test was used for nominal data and Student t-test for continuous data. 2017 Nov 15;8(1):263. doi: 10.1186/s13287-017-0711-2. Clinical Pharmacist, Department of Pharmacy. USA.gov. Summary of comparisons in the time benefit and prediction rates obtained from each candidate parameter related to platelet recovery after hematopoietic stem cell transplantation in total 44 patients. Furthermore, the donor source and type of allogeneic transplant received were also not reported. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Patients were identified via an internal stem-cell transplant patient database and the institution’s electronic medical record. 1994 Apr;12(4):650-2. doi: 10.1200/JCO.1994.12.4.650. Get the latest research from NIH: https://www.nih.gov/coronavirus. Patients and methods: Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. The rash can spread and is usually itchy and dry. Bone Marrow Transplant 33, … Differences that may exist between the routes of administration of G-CSF may be difficult to elucidate in such a small population, especially when trying to discern variances in specific transplant type. Epub 2018 May 17. NIH In addition, no differences in the secondary outcomes were found, including the time to neutrophil engraftment between autologous and allogeneic HSCT, the incidence of febrile neutropenia, incidence of documented infection, in-hospital all-cause mortality, and length of hospital stay. Working off-campus? In addition, the patient population was heterogeneous; the disease type, conditioning regimens, donor source, and type of allogeneic transplant patients received may have affected the outcomes, independently of the route of administration of G-CSF and were not always balanced in the 2 arms of the study. Evaluation of parameters obtained from the Sysmex XN‐2000 for predicting the recovery of the absolute neutrophil count and platelets after hematopoietic stem cell transplantation S.‐H. There was no significant difference between the two study arms in the duration of fever, documented septic episodes, or RBC or platelet transfusion requirements. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Urine cultures were positive in 14.3% of patients in the SQ arm who had cultures collected compared with 8.3% of patients in the IV arm.